Treats insomnia characterized. ANDA 78413, held by Aurobindo Pharma. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 78413 (Zolpidem Tartrate), held by Aurobindo Pharma, was first approved by FDA on May 4, 2007, with 12 approved supplements and 0 published complete response letters.
Zolpidem tartrate tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate tablets have been shown to decrease sleep latency for up to 35 days in controlled clinical studies. The clinical trials performed in support of efficacy were 4 to 5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 4, 2007 | Original application | Approved | None posted |
| Zolpidem Tartrate5MG · tablet;oral | Zolpidem Tartrate | Rx |
| Zolpidem Tartrate10MG · tablet;oral | Zolpidem Tartrate | Rx |
| Sep 2, 2022 | Supplement 23Labeling · Standard review | Approved | None posted |
| Sep 19, 2019 | Supplement 19Labeling · Standard review | Approved | None posted |
| Sep 19, 2019 | Supplement 16Labeling · Standard review | Approved | None posted |
| Sep 19, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 19, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 19, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 19, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Mar 19, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 11, 2013 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 9, 2011 | Supplement 5Manufacturing | Approved | None posted |
| Aug 18, 2010 | Supplement 4Labeling | Approved | None posted |
| Jan 23, 2009 | Supplement 3Labeling | Approved | None posted |
| May 4, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters